Laboratory-confirmed gonorrhea and/or chlamydia rates in clinically diagnosed pelvic inflammatory disease and cervicitis
- PMID: 22030186
- DOI: 10.1016/j.ajem.2011.07.014
Laboratory-confirmed gonorrhea and/or chlamydia rates in clinically diagnosed pelvic inflammatory disease and cervicitis
Abstract
Objective: The aim of this study was to determine the rates of laboratory confirmed gonorrhea (GC) and chlamydia (CT) in emergency department (ED) patients with pelvic inflammatory disease (PID) and cervicitis who were diagnosed clinically and treated empirically. A secondary goal examines which clinical criteria were present in patients with PID testing positive for GC/CT.
Methods: We conducted a retrospective chart review of all ED patents diagnosed with PID or cervicitis during a 40-month period (January 2007-March 2010). Charts were reviewed for laboratory-confirmed GC or CT. For patients with positive GC or CT studies, the presence of key clinical criteria used in the diagnosis of PID was tallied.
Results: A total of 1469 patients were diagnosed with cervicitis and 343 with PID. Of these patients, 27 (1.8%) of 1469 and 15 (4.4%) of 343 were GC positive, and 136 (9.3%) of 1469 and 34 (10%) of 343 were CT positive. Twenty-six cervicitis (1.8%) and 9 PID (2.6%) patients were positive for both infections. One hundred eighty-nine cervicitis (13%) and 58 PID (17%) patients were positive for at least 1 sexually transmitted infection. Of the 58 patients with PID with laboratory-confirmed GC/CT, the following clinical criteria were present: abdominal pain, 58 of 58; abdominal tenderness, 50 of 58; cervical discharge, 47 of 58; cervical motion tenderness, 46 of 58; adnexal tenderness, 32 of 58; vaginal bleeding, 8 of 58; and fever, 2 of 58. Ultrasound was preformed in 27 (47%) of 58 GC/CT-positive patients with PID, with findings suggestive of PID in 12 (44%) of 27 ultrasounds. One hundred percent of abnormal ultrasounds were associated with positive GC and/or CT results.
Conclusion: There is a generally low prevalence of GC and CT in this patient population diagnosed with cervicitis or PID. There is a very low prevalence of coinfection.
Copyright © 2012 Elsevier Inc. All rights reserved.
Similar articles
-
Underrecognition of cervical Neisseria gonorrhoeae and Chlamydia trachomatis infections in pregnant patients in the ED.Am J Emerg Med. 2013 Apr;31(4):661-3. doi: 10.1016/j.ajem.2012.11.017. Epub 2013 Feb 5. Am J Emerg Med. 2013. PMID: 23391639
-
Pelvic inflammatory disease in the adolescent: understanding diagnosis and treatment as a health care provider.Pediatr Emerg Care. 2013 Jun;29(6):720-5. doi: 10.1097/PEC.0b013e318294dd7b. Pediatr Emerg Care. 2013. PMID: 23714759
-
Hormonal and barrier contraception and risk of upper genital tract disease in the PID Evaluation and Clinical Health (PEACH) study.Am J Obstet Gynecol. 2001 Jul;185(1):121-7. doi: 10.1067/mob.2001.115114. Am J Obstet Gynecol. 2001. PMID: 11483915
-
Acute pelvic inflammatory disease.Urol Clin North Am. 1984 Feb;11(1):65-81. Urol Clin North Am. 1984. PMID: 6369707 Review.
-
Epidemiology of Chlamydia trachomatis infection in women and the cost-effectiveness of screening.Hum Reprod Update. 2010 Mar-Apr;16(2):189-204. doi: 10.1093/humupd/dmp035. Epub 2009 Oct 14. Hum Reprod Update. 2010. PMID: 19828674 Review.
Cited by
-
A Novel Platform Using RNA Signatures To Accelerate Antimicrobial Susceptibility Testing in Neisseria gonorrhoeae.J Clin Microbiol. 2020 Nov 18;58(12):e01152-20. doi: 10.1128/JCM.01152-20. Print 2020 Nov 18. J Clin Microbiol. 2020. PMID: 32967905 Free PMC article.
-
Repurposing salicylamide for combating multidrug-resistant Neisseria gonorrhoeae.Antimicrob Agents Chemother. 2019 Sep 9;63(12):e01225-19. doi: 10.1128/AAC.01225-19. Epub 2019 Sep 30. Antimicrob Agents Chemother. 2019. PMID: 31570391 Free PMC article.
-
In vivo efficacy of acetazolamide in a mouse model of Neisseria gonorrhoeae infection.Microb Pathog. 2022 Mar;164:105454. doi: 10.1016/j.micpath.2022.105454. Epub 2022 Feb 19. Microb Pathog. 2022. PMID: 35189278 Free PMC article.
-
Antibacterial Activity of Chitosan Nanoparticles Against Pathogenic N. gonorrhoea.Int J Nanomedicine. 2020 Oct 13;15:7877-7887. doi: 10.2147/IJN.S272736. eCollection 2020. Int J Nanomedicine. 2020. PMID: 33116506 Free PMC article.
-
Global burden of pelvic inflammatory disease and ectopic pregnancy from 1990 to 2019.BMC Public Health. 2023 Oct 2;23(1):1894. doi: 10.1186/s12889-023-16663-y. BMC Public Health. 2023. PMID: 37784046 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous